Seeking Alpha

Acadia Pharmaceuticals (ACAD) soars 51% after saying that the results of a Phase III trial of...

Acadia Pharmaceuticals (ACAD) soars 51% after saying that the results of a Phase III trial of its Pimavanserin drug, plus other data, are enough for the company to file an application for FDA approval. Acadia will not now conduct a confirmatory phase III trial that was due to start this month. Pimavanserin is designed to treat Parkinson's disease psychosis. (PR)
Comments (4)
  • GaryLee276
    , contributor
    Comments (153) | Send Message
     
    I am out at $11.70. I got out a little early but I feel good about this trade. I would like to aGAIN thank Scott Matusow for his article.
    11 Apr 2013, 08:16 AM Reply Like
  • fafatooey
    , contributor
    Comments (395) | Send Message
     
    You won't see $11.70 again.
    11 Apr 2013, 04:54 PM Reply Like
  • bob1000000
    , contributor
    Comments (31) | Send Message
     
    Dips are inevitable after big runups, but ACAD's story is just beginning. Next 2 years has much more potential. Will be looking to add to core position when it does pullback.
    11 Apr 2013, 09:58 PM Reply Like
  • GaryLee276
    , contributor
    Comments (153) | Send Message
     
    They are not submitting their NDA for over a year. What is going to hold the stock up?
    12 Apr 2013, 05:12 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs